Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
REGULATED INFORMATION
GHENT, Belgium, 18 January 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 154,342 common shares have been issued by the Company in exchange for €1,011,939.05 as the result of the exercise of warrants.
As a result of this transaction, Ablynx now has 61,076,074 shares outstanding.
The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights currently is 2,457,038 which equals the total number of voting rights that may result from the exercise of these warrants. Currently 1,000 convertible bonds are outstanding entitling the holders thereof to 7,733,952 shares of the Company in the aggregate, upon conversion of such convertible bonds.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: [email protected]
Marieke Vermeersch
Director IR & Corporate Communications
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: [email protected]
Follow us on Twitter @AblynxABLX
Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: [email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/042f367b-8978-426d-b814-9d13c302ca73
